![Abhinav Jain](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Abhinav Jain
Directeur/Bestuurslid bij
AYTU BIOPHARMA, INC.
Vermogen: 123 960 $ op 31-05-2026
Profiel
Mr. Abhinav Jain is an Independent Director at Eagle Pharmaceuticals, Inc., an Independent Director at Talphera, Inc. and an Independent Director at Aytu Biopharma, Inc. He is on the Board of Directors at Eagle Pharmaceuticals, Inc., Xtant Medical Holdings, Inc., Talphera, Inc. and Aytu Biopharma, Inc. Mr. Jain was previously employed as an Associate by Angelo, Gordon & Co. LP.
He received his undergraduate degree from Massachusetts Institute of Technology and an MBA from The Wharton School of the University of Pennsylvania.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 15-11-2025 | 158.228 ( 0,11% ) | 73 101 $ | 31-05-2026 | |
AYTU BIOPHARMA, INC. 0,18% | 13-10-2025 | 19.500 ( 0,18% ) | 44 655 $ | 31-05-2026 |
TALPHERA, INC. 0,02% | 24-04-2026 | 7.602 ( 0,02% ) | 6 203 $ | 31-05-2026 |
Actieve functies van Abhinav Jain
| Bedrijven | Functie | Begin |
|---|---|---|
| AYTU BIOPHARMA, INC. | Directeur/Bestuurslid | 12-06-2023 |
| TALPHERA, INC. | Directeur/Bestuurslid | 22-01-2024 |
| XTANT MEDICAL HOLDINGS, INC. | Directeur/Bestuurslid | 01-08-2025 |
| EAGLE PHARMACEUTICALS, INC. | Directeur/Bestuurslid | 28-08-2025 |
Eerdere bekende functies van Abhinav Jain
| Bedrijven | Functie | Einde |
|---|---|---|
Angelo, Gordon & Co. LP
 Angelo, Gordon & Co. LP Investment ManagersFinance TPG Angelo Gordon seeks alternative investment opportunities that will deliver consistent absolute returns for their clients. The firm manages capital across their Credit and Real Estate strategies, all of which employ a disciplined investment philosophy that combines fundamental in-depth research with a diversification strategy 20 designed to reduce downside risk. The research team is the cornerstone of all investment activities. | Corporate Officer/Principal | 01-01-2017 |
Opleiding van Abhinav Jain
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
63
Eerstegraads connecties
7
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 7 |
|---|---|
Angelo, Gordon & Co. LP
Angelo, Gordon & Co. LP Investment ManagersFinance TPG Angelo Gordon seeks alternative investment opportunities that will deliver consistent absolute returns for their clients. The firm manages capital across their Credit and Real Estate strategies, all of which employ a disciplined investment philosophy that combines fundamental in-depth research with a diversification strategy 20 designed to reduce downside risk. The research team is the cornerstone of all investment activities. | Finance |
Eagle Pharmaceuticals, Inc.
 Eagle Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercialize injectable products primarily in the metabolic critical care and oncology | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Talphera, Inc.
 Talphera, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical products | Health Technology |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aytu Biopharma, Inc.
 Aytu Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Xtant Medical Holdings, Inc.
 Xtant Medical Holdings, Inc. Medical SpecialtiesHealth Technology Manufactures and commercializes surgical products | Health Technology |
